PCM
ATRC icon

Prelude Capital Management’s AtriCure ATRC Stock Holding History

Prelude Capital Management’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,000
Closed -$41K – 1686
2015
Q1 		$41K Buy
+2,000
New +$38.7K 0.01% 1404

Other funds holding ATRC

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's ATRC Position: Q1 2026 in Review

Prelude Capital Management sold out of AtriCure (ATRC) in Q1 2026, closing a stake of 6,095 shares — an estimated $241K sold.

Prelude Capital Management first reported a position in ATRC in Q1 2015 and held it in 26 quarters. The position peaked at $1.16M in Q4 2023. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • Prelude Capital Management reported no remaining AtriCure position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 6,095 AtriCure shares in Q1 2026, an estimated $241K.
  • Prelude Capital Management first reported a position in AtriCure in Q1 2015 and held it in 26 quarters.
  • Prelude Capital Management's AtriCure position peaked at $1.16M in Q4 2023.
  • 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.